---
title: "Is CRISPR Therapeutics (CRSP) Attractive After Recent Share Price Weakness And DCF Upside?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280042499.md"
description: "CRISPR Therapeutics (CRSP) is currently priced at approximately $46.24, showing a 12.2% increase over the past year but a decline of 5.1% in the last week and 14.0% year-to-date. A Discounted Cash Flow (DCF) analysis indicates the stock is undervalued by 75.6%, with an intrinsic value of $189.45 per share. The company has a price-to-book (P/B) ratio of 2.31, slightly below the industry average, suggesting a lower market valuation compared to peers. Investors are encouraged to assess the company's long-term potential amidst current market fluctuations."
datetime: "2026-03-22T06:17:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280042499.md)
  - [en](https://longbridge.com/en/news/280042499.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280042499.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/280042499.md) | [繁體中文](https://longbridge.com/zh-HK/news/280042499.md)


# Is CRISPR Therapeutics (CRSP) Attractive After Recent Share Price Weakness And DCF Upside?

-   Wondering whether CRISPR Therapeutics at around US$46.24 is offering good value, or if the recent excitement is already priced in? This breakdown is designed to help you frame that question clearly.
-   The stock is up 12.2% over the past year, even though it shows a 5.1% decline over 7 days, a 13.5% decline over 30 days, and a 14.0% decline year to date. Recent trading has therefore looked quite different to the longer term picture.
-   Recent headlines around CRISPR Therapeutics have focused on its role in gene editing and progress in its treatment pipeline, which keeps attention on potential long term value creation. At the same time, regulatory developments and sentiment around biotech risk have also been part of the backdrop investors are weighing.
-   CRISPR Therapeutics currently has a valuation score of 4/6. The next sections will break this down across different valuation methods, before finishing with a broader framework that can help you assess its value more completely.

Find out why CRISPR Therapeutics's 12.2% return over the last year is lagging behind its peers.

### Approach 1: CRISPR Therapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth today by projecting its future cash flows and discounting them back to a single present value figure.

For CRISPR Therapeutics, the latest twelve month free cash flow (FCF) is a loss of $345.4 million. Analysts provide FCF estimates for several years, and those are extended using a 2 Stage Free Cash Flow to Equity model. Under these projections, FCF is expected to reach $204.5 million in 2030, with interim years moving from losses in the hundreds of millions of dollars to positive cash generation.

When all projected cash flows are discounted back and combined, the model produces an estimated intrinsic value of about $189.45 per share. Compared with the current share price of around $46.24, this implies CRISPR Therapeutics is trading at a 75.6% discount to this DCF estimate. This indicates a wide gap between the modelled value and the current market price.

**Result: UNDERVALUED**

Our Discounted Cash Flow (DCF) analysis suggests CRISPR Therapeutics is undervalued by 75.6%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.

CRSP Discounted Cash Flow as at Mar 2026

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for CRISPR Therapeutics.

### Approach 2: CRISPR Therapeutics Price vs Book

For companies where earnings are volatile or negative, price-based multiples that focus on assets, such as the price to book or P/B ratio, can be more informative than P/E. They help you compare what the market is paying for each dollar of net assets, without relying on current profitability.

In general, the higher the growth expectations and the lower the perceived risk, the higher a “normal” valuation multiple investors may be willing to pay. The opposite is also true, as slower growth or higher risk usually points to a lower multiple being seen as reasonable.

CRISPR Therapeutics currently trades on a P/B of 2.31x. This sits slightly below the Biotechs industry average P/B of 2.47x, and also well below the peer group average of 8.05x. This suggests the market is assigning a lower value to its equity base than many peers. Simply Wall St also uses a proprietary “Fair Ratio” metric, which estimates what a suitable P/B multiple could be after factoring in elements such as earnings growth, profit margins, industry, market capitalization and key risks.

Because the Fair Ratio framework adjusts for these company-specific drivers, it can give a more tailored reference point than a simple comparison with industry or peer averages, which may mix together businesses with very different growth profiles and risk levels.

**Result: ABOUT RIGHT**

NasdaqGM:CRSP P/B Ratio as at Mar 2026

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

### Upgrade Your Decision Making: Choose your CRISPR Therapeutics Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so this is where Narratives come in.

A Narrative is simply your story for a company, tying together your view on its products, competitive position and risks with your own assumptions for future revenue, earnings and profit margins, which then feed into an estimated fair value.

On Simply Wall St’s Community page, used by millions of investors, Narratives give you an accessible way to connect that story to a clear financial forecast and a fair value figure. You can then compare that fair value to the current share price to help decide whether you see CRISPR Therapeutics as priced attractively, fully priced or expensive.

Narratives are updated when new information such as company news or earnings is added to the platform, so your story and numbers can evolve rather than staying fixed. For example, you can see one CRISPR Therapeutics Narrative that prices in very optimistic uptake for its gene editing pipeline and another that assumes slower adoption and higher regulatory risk. These can lead to very different fair value estimates even though both are built from the same current share price and disclosures.

Do you think there's more to the story for CRISPR Therapeutics? Head over to our Community to see what others are saying!

NasdaqGM:CRSP 1-Year Stock Price Chart

_This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

### **New:** AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)  
• Undervalued Small Caps with Insider Buying  
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

### Related Stocks

- [WisdomTree BioRevolution ETF (WDNA.US)](https://longbridge.com/en/quote/WDNA.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [CRISPR Therapeutics AG (CRSP.US)](https://longbridge.com/en/quote/CRSP.US.md)
- [iShares Genomics Immnlgy & Hlthcr ETF (IDNA.US)](https://longbridge.com/en/quote/IDNA.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [Direxion Daily S&P Biotech Bull 3X ETF (LABU.US)](https://longbridge.com/en/quote/LABU.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [ARK Innovation ETF (ARKK.US)](https://longbridge.com/en/quote/ARKK.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [Running Oak Efficient Growth ETF (RUNN.US)](https://longbridge.com/en/quote/RUNN.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [Assessing CRISPR Therapeutics (CRSP) Valuation After CASGEVY Traction And US$600m Convertible Notes Raise](https://longbridge.com/en/news/279876016.md)
- [Regulatory Disruptions Pose Material Operational Risks for Milestone Pharmaceuticals](https://longbridge.com/en/news/280011451.md)
- [Azitra CEO-backed private placement priced up to $10.5M, potential $20.9M; stock jumps 90%](https://longbridge.com/en/news/279939021.md)
- [CRISPR-Integrated Gene Editing Delivery Devices Market Outlook 2026-2036: Global Market to Reach USD 4.41 Billion by 2036 at 14.10% CAGR](https://longbridge.com/en/news/279758762.md)
- [Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update | BFRI Stock News](https://longbridge.com/en/news/279798639.md)